<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="56" ids="16716">Benzene</z:chebi> exposure is associated with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and probably <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and childhood <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Biological plausibility for a causal role of <z:chebi fb="56" ids="16716">benzene</z:chebi> in these diseases comes from its toxicity to hematopoietic stem cells (<z:chebi fb="15" ids="50443">HSC</z:chebi>) or progenitor cells, from which <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0001909'>leukemias</z:hpo> and related disorders arise </plain></SENT>
<SENT sid="2" pm="."><plain>The effect of this toxicity is manifest as lowered blood counts (hematotoxicity), even in individuals occupationally exposed to low levels of <z:chebi fb="56" ids="16716">benzene</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="56" ids="16716">Benzene</z:chebi> can induce <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> via several well-characterized pathways associated with these diseases </plain></SENT>
<SENT sid="4" pm="."><plain>Through its metabolites, <z:chebi fb="56" ids="16716">benzene</z:chebi> induces multiple alterations that likely contribute to the leukemogenic process, and appears to operate via multiple modes of action </plain></SENT>
<SENT sid="5" pm="."><plain>To improve mechanistic understanding and for risk assessment purposes, it may be possible to measure several of the key events in these modes of action in an in vitro model of the bone marrow stem cell niche </plain></SENT>
<SENT sid="6" pm="."><plain>Even though <z:chebi fb="56" ids="16716">benzene</z:chebi> is leukemogenic at relatively low occupational levels of exposure, it seems unlikely that it is a major cause of <z:hpo ids='HP_0001909'>leukemia</z:hpo> in the general population exposed to <z:chebi fb="56" ids="16716">benzene</z:chebi> in the ppb range </plain></SENT>
<SENT sid="7" pm="."><plain>Other established non-genetic causes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, e.g. smoking, ionizing radiation and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> chemotherapy, also only explain about 20% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> incidence, leaving âˆ¼80% unexplained </plain></SENT>
<SENT sid="8" pm="."><plain>The question arises as to how to find the causes of the majority of de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMLs</z:e> that remain unexplained </plain></SENT>
<SENT sid="9" pm="."><plain>We propose that we should attempt to characterize the 'exposome' of human <z:hpo ids='HP_0001909'>leukemia</z:hpo> by using unbiased laboratory-based methods to find the unknown 'environmental' factors that contribute to <z:hpo ids='HP_0001909'>leukemia</z:hpo> etiology </plain></SENT>
</text></document>